IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy

S. Peters, A. W. Kim, B. Solomon, D. R. Gandara, R. Dziadziuszko, A. Brunelli, M. C. Garassino, M. Reck, L. Wang, I. To, S. W. Sun, B. J. Gitlitz, A. Sandler, N. Rizvi

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)ii30
JournalAnnals of Oncology
Volume30
DOIs
StatePublished - Apr 2019

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Peters, S., Kim, A. W., Solomon, B., Gandara, D. R., Dziadziuszko, R., Brunelli, A., Garassino, M. C., Reck, M., Wang, L., To, I., Sun, S. W., Gitlitz, B. J., Sandler, A., & Rizvi, N. (2019). IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy. Annals of Oncology, 30, ii30. https://doi.org/10.1093/annonc/mdz064.014